Status:
COMPLETED
Evaluation of Delirium Prevention in Critically Ill Patients
Lead Sponsor:
Radboud University Medical Center
Conditions:
Delirium
Eligibility:
All Genders
18+ years
Brief Summary
Haloperidol is prescribed in high risk ICU patients concerning delirium (50% or more chance to develop delirium detected with the delirium prediction model PRE-DELIRIC, or patients with history of dem...
Detailed Description
Measurement the effect of haloperidol as delirium preventive intervention. Determining effect on: \- delirium incidence in the ICU - different subtypes of delirium - delirium free days in 28 days - d...
Eligibility Criteria
Inclusion
- Patients With Predicted Delirium Chance of \>50% or history of dementia or alcohol abuse and treated with haloperidol
Exclusion
- CAM-ICU is Not Applicable
- Patients Admitted 24hours or Shorter on the ICU, Patients Who Are Delirious Within 24 Hours After ICU Admission
- patients whereby haloperidol is contra-indicated
Key Trial Info
Start Date :
August 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 1 2011
Estimated Enrollment :
650 Patients enrolled
Trial Details
Trial ID
NCT01187667
Start Date
August 1 2010
End Date
October 1 2011
Last Update
August 10 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Radboud University Nijmegen Medical Centre
Nijmegen, Netherlands, 6500HB